More recently, we investigated the effects of the SGLT-2 inhibitor dapagliflozin on glucose metabolism in a mouse model of NASH with concurrent type 2 diabetes. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatohepatitis.